NEW YORK (GenomeWeb) – Cantor Fitzgerald has initiated coverage of NeoGenomics with an Overweight rating and a price target of $11.

The investment bank said NeoGenomics' "transformational acquisition" of Clarient last year has moved the company into a leadership position in the cancer diagnostics market, "with improved economies of scale, a broadened testing portfolio, an expanded geographic reach, and ongoing relationship with GE Healthcare."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.